These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 1884731)
1. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure. Markus H; Cowley AJ Eur J Clin Pharmacol; 1991; 40(6):535-8. PubMed ID: 1884731 [TBL] [Abstract][Full Text] [Related]
2. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure. Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928 [TBL] [Abstract][Full Text] [Related]
3. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects. Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507 [TBL] [Abstract][Full Text] [Related]
4. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy. Dakak N; Makhoul N; Merdler A; Yechiely H; Kahana L; Halon DA; Schneeweiss A; Lewis BS Eur Heart J; 1993 Jun; 14(6):836-44. PubMed ID: 8325314 [TBL] [Abstract][Full Text] [Related]
5. The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction. Schneeweiss A; Wynne RD; Marmor A Jpn Heart J; 1989 Sep; 30(5):627-34. PubMed ID: 2614925 [TBL] [Abstract][Full Text] [Related]
6. Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance. Starling MR Am Heart J; 1994 Jul; 128(1):124-33. PubMed ID: 8017265 [TBL] [Abstract][Full Text] [Related]
7. Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers. Duranteau J; Pussard E; Edouard A; Samii K; Berdeaux A; Giudicelli JF Br J Clin Pharmacol; 1992 Sep; 34(3):207-14. PubMed ID: 1389945 [TBL] [Abstract][Full Text] [Related]
8. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Lapp H; Mitrovic V; Franz N; Heuer H; Buerke M; Wolfertz J; Mueck W; Unger S; Wensing G; Frey R Circulation; 2009 Jun; 119(21):2781-8. PubMed ID: 19451356 [TBL] [Abstract][Full Text] [Related]
9. Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure. Thomas P; O'Gorman DJ; Sheridan DJ Br J Clin Pharmacol; 1993 Dec; 36(6):539-46. PubMed ID: 12959270 [TBL] [Abstract][Full Text] [Related]
10. Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure. Isnard R; Lechat P; Pousset F; Carayon A; Kalotka H; Chikr H; Salloum J; Thomas D; Komajda M Fundam Clin Pharmacol; 1997; 11(1):83-9. PubMed ID: 9182081 [TBL] [Abstract][Full Text] [Related]
11. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure. Kessler PD; Packer M; Medina N; Yushak M J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536 [TBL] [Abstract][Full Text] [Related]
12. Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure. Bartels GL; Remme WJ; Wiesfeld AC; Kok FJ; Look MP; Krauss XH; Kruyssen HA Cardiovasc Drugs Ther; 1990 Jun; 4(3):705-12. PubMed ID: 2076381 [TBL] [Abstract][Full Text] [Related]
13. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070 [TBL] [Abstract][Full Text] [Related]
14. Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans. Giles TD; Pina IL; Quiroz AC; Roffidal L; Zaleski R; Porter RS; Karalis DG; Mohrland JS; Wolf DL; Hearron AE J Cardiovasc Pharmacol; 1992 Oct; 20(4):572-8. PubMed ID: 1280713 [TBL] [Abstract][Full Text] [Related]
16. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure. Bartels GL; Remme WJ; Look MP; Kruijssen DA J Card Fail; 1995 Mar; 1(2):117-25. PubMed ID: 9420641 [TBL] [Abstract][Full Text] [Related]
17. The effect of flosequinan in patients with heart failure of acute onset complicating acute myocardial infarction. Schneeweiss A; Wynne RD; Marmor A Int J Cardiol; 1989 Jul; 24(1):73-6. PubMed ID: 2668206 [TBL] [Abstract][Full Text] [Related]
18. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog. Greenberg S; Touhey B J Cardiovasc Pharmacol; 1990 Jun; 15(6):900-10. PubMed ID: 1694912 [TBL] [Abstract][Full Text] [Related]
19. Acute and long-term effects of flosequinan in patients with chronic cardiac failure. Marchionni N; Moschi G; Di Bari M; Burgisser C; Fumagalli S; Boncinelli L; Tarantini F; Ferrucci L Am Heart J; 1993 Jul; 126(1):147-54. PubMed ID: 8322657 [TBL] [Abstract][Full Text] [Related]
20. Effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction. Schneeweiss A; Wynne RD; Marmor A Crit Care Med; 1989 Sep; 17(9):879-81. PubMed ID: 2766758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]